Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-102 (Semdexa) Pharmacodynamics and Safety in Lumbosacral Radiculopathy
NCT03613662Phase 2Completed
- Sponsor
- Semnur Pharmaceuticals, Inc.
- Start
- Jul 2018
- Primary completion
- Mar 2019
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of semdexa in lumbosacral radiculopathy, sponsored by Semnur Pharmaceuticals, Inc. Primary endpoints: Change in Plasma Cortisol Concentrations From Baseline at 12 weeks, Change in Blood Glucose Levels From Baseline at 12 weeks and 1 more. Started Jul 2018; status: completed.
02
Drugs
semdexa
03
Conditions
lumbosacral radiculopathy
Beyond the preview
Go deeper on NCT03613662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03613662.